➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Johnson and Johnson
Harvard Business School
Medtronic
Boehringer Ingelheim

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,058,610

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,058,610
Title:Methods for treating cancer by administering humanized pan-HER antibody compositions
Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
Inventor(s): Lantto; Johan (Lund, SE), Andersen; Kim Vilbour (Bronshoj, DK), Andersen; Peter Sejer (Vanlose, DK), Strandh; Magnus (Malmo, SE), Koefoed; Klaus (Kobenhavn S, DK), Nielsen; Lars Sogaard (Niva, DK), Pedersen; Mikkel Wandahl (Alleroed, DK), Jacobsen; Helle (Virum, DK), Kragh; Michael (Copenhagen, DK), Kjaer; Ida (Copenhagen, DK), Poulsen; Thomas Tuxen (Dyssegaard, DK)
Assignee: Symphogen A/S (Ballerup, DK)
Application Number:15/350,801
Patent Claims:1. A method for treating cancer in a human patient, the method comprising administering to said patient an effective amount of an antibody composition comprising: a) an anti-epidermal growth factor receptor (EGFR) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 42 and 43, respectively, SEQ ID NOs: 38 and 39, respectively, SEQ ID NOs: 40 and 41, respectively, SEQ ID NOs: 44 and 45, respectively, or SEQ ID NOs: 46 and 47, respectively; b) an anti-human epidermal growth factor receptor 2 (HER2) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 50 and 51, respectively, SEQ ID NOs: 48 and 49, respectively, or SEQ ID NOs: 52 and 53, respectively; and c) an anti-human epidermal growth factor receptor 3 (HER3) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 54 and 55, respectively, SEQ ID NOs: 56 and 57, respectively, SEQ ID NOs: 58 and 59, respectively, or SEQ ID NOs: 60 and 61, respectively.

2. The method of claim 1, wherein said antibody composition comprises: a) an anti-epidermal growth factor receptor (EGFR) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 38 and 39, respectively, SEQ ID NOs: 40 and 41, respectively, or SEQ ID NOs: 42 and 43, respectively; b) an anti-EGFR antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 44 and 45, respectively, or SEQ ID NOs: 46 and 47, respectively; c) an anti-human epidermal growth factor receptor 2 (HER2) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 48 and 49, respectively, or SEQ ID NOs: 50 and 51, respectively; d) an anti-HER2 antibody comprising a heavy chain that comprises the amino acid sequence of SEQ ID NO: 52 and a light chain that comprises the amino acid sequence of SEQ ID NO: 53; e) an anti-human epidermal growth factor receptor 3 (HER3) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 54 and 55, respectively, or SEQ ID NOs: 56 and 57, respectively; and f) an anti-HER3 antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 58 and 59, respectively, or SEQ ID NOs: 60 and 61, respectively.

3. The method of claim 1, wherein said antibody composition has at least one of the following properties: a) inhibits cancer growth in the patient; b) reduces EGFR, HER2, or HER3 expression in cancer cells in the patient; and c) prevents EGFR, HER2, or HER3 up-regulation in cancer cells in the patient.

4. The method of claim 1, wherein the patient has pancreatic cancer, lung cancer, head and neck cancer, breast cancer, gastric cancer, colorectal cancer, esophageal cancer, or ovarian cancer.

5. The method of claim 1, wherein the patient has pancreatic cancer and a KRAS mutation.

6. The method of claim 1, wherein at least one of the antibodies is conjugated to an anti-cancer agent.

7. The method of claim 1, wherein the patient has been treated for cancer previously.

8. The method of claim 1, wherein said patient has acquired resistance to treatment with an antibody and/or a tyrosine kinase inhibitor.

9. The method of claim 8, wherein the antibody is cetuximab, trastuzumab, or pertuzumab.

10. A method for treating cancer in a human patient, the method comprising administering to said patient an effective amount of an antibody composition comprising: a) an anti-epidermal growth factor receptor (EGFR) antibody comprising the heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 42 and the light chain variable region (VL) amino acid sequence of SEQ ID NO: 43; b) an anti-EGFR antibody comprising the VH amino acid sequence of SEQ ID NO: 46 and the VL amino acid sequence of SEQ ID NO: 47; c) an anti-human epidermal growth factor receptor 2 (HER2) antibody comprising the VH amino acid sequence of SEQ ID NO: 50 and the VL amino acid sequence of SEQ ID NO: 51; d) an anti-HER2 antibody comprising the VH amino acid sequence of SEQ ID NO: 52 and the VL amino acid sequence of SEQ ID NO: 53; e) an anti-human epidermal growth factor receptor 3 (HER3) antibody comprising the VH amino acid sequence of SEQ ID NO: 54 and the VL amino acid sequence of SEQ ID NO: 55; and f) an anti-HER3 antibody comprising the VH amino acid sequence of SEQ ID NO: 60 and the VL amino acid sequence of SEQ ID NO: 61.

11. The method of claim 10, wherein said antibody composition has at least one of the following properties: a) inhibits cancer growth in the patient; b) reduces EGFR, HER2, or HER3 expression in cancer cells in the patient; and c) prevents EGFR, HER2, or HER3 up-regulation in cancer cells in the patient.

12. The method of claim 10, wherein the patient has pancreatic cancer, lung cancer, head and neck cancer, breast cancer, gastric cancer, colorectal cancer, esophageal cancer, or ovarian cancer.

13. The method of claim 10, wherein the patient has pancreatic cancer and a KRAS mutation.

14. The method of claim 10, wherein at least one of the antibodies is conjugated to an anti-cancer agent.

15. The method of claim 10, wherein the patient has been treated for cancer previously.

16. The method of claim 10, wherein said patient has acquired resistance to treatment with an antibody and/or a tyrosine kinase inhibitor.

17. The method of claim 16, wherein the antibody is cetuximab, trastuzumab, or pertuzumab.

18. A method for treating a human patient with a disorder characterized by overexpression of EGFR, HER2, and/or HER3, the method comprising administering to said patient an effective amount of an antibody composition comprising: a) an anti-epidermal growth factor receptor (EGFR) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 42 and 43, respectively, SEQ ID NOs: 38 and 39, respectively, SEQ ID NOs: 40 and 41, respectively, SEQ ID NOs: 44 and 45, respectively, or SEQ ID NOs: 46 and 47, respectively; b) an anti-human epidermal growth factor receptor 2 (HER2) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 50 and 51, respectively, SEQ ID NOs: 48 and 49, respectively, or SEQ ID NOs: 52 and 53, respectively; and c) an anti-human epidermal growth factor receptor 3 (HER3) antibody comprising a heavy chain and a light chain that comprise the amino acid sequences of: SEQ ID NOs: 54 and 55, respectively, SEQ ID NOs: 56 and 57, respectively, SEQ ID NOs: 58 and 59, respectively, or SEQ ID NOs: 60 and 61, respectively.

19. The method of claim 18, wherein said antibody composition comprises: a) an anti-epidermal growth factor receptor (EGFR) antibody comprising the heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 42 and the light chain variable region (VL) amino acid sequence of SEQ ID NO: 43; b) an anti-EGFR antibody comprising the VH amino acid sequence of SEQ ID NO: 46 and the VL amino acid sequence of SEQ ID NO: 47; c) an anti-human epidermal growth factor receptor 2 (HER2) antibody comprising the VH amino acid sequence of SEQ ID NO: 50 and the VL amino acid sequence of SEQ ID NO: 51; d) an anti-HER2 antibody comprising the VH amino acid sequence of SEQ ID NO: 52 and the VL amino acid sequence of SEQ ID NO: 53; e) an anti-human epidermal growth factor receptor 3 (HER3) antibody comprising the VH amino acid sequence of SEQ ID NO: 54 and the VL amino acid sequence of SEQ ID NO: 55; and f) an anti-HER3 antibody comprising the VH amino acid sequence of SEQ ID NO: 60 and the VL amino acid sequence of SEQ ID NO: 61.

20. The method of claim 18, wherein said antibody composition has at least one of the following properties: a) reduces EGFR, HER2, or HER3 expression in cancer cells in the patient; and b) prevents EGFR, HER2, or HER3 up-regulation in cancer cells in the patient.

Details for Patent 10,058,610

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX Orphan search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
Merck
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.